|
1
|
Kruijtzer CM, Beijnen JH and Schellens JH:
Improvement of oral drug treatment by temporary inhibition of drug
transporters and/or cytochrome P450 in the gastrointestinal tract
and liver: an overview. Oncologist. 7:516–530. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Casarett LJ and Doull J: Toxicology: The
Basic Science of Poisons. Macmillan Publishing Company; London, UK:
1975
|
|
3
|
Anzenbacher P and Anzenbacherová E:
Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci.
58:737–747. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stevens JC, Hines RN, Gu C, et al:
Developmental expression of the major human hepatic CYP3A enzymes.
J Pharmacol Exp Ther. 307:573–582. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo G, Cunningham M, Kim S, et al: CYP3A4
induction by drugs: correlation between a pregnane X receptor
reporter gene assay and CYP3A4 expression in human hepatocytes.
Drug Metab Dispos. 30:795–804. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Katoh M, Nakajima M, Yamazaki H and Yokoi
T: Inhibitory effects of CYP3A4 substrates and their metabolites on
P-glycoprotein-mediated transport. Eur J Pharm Sci. 12:505–513.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kivistö KT, Niemi M and Fromm MF:
Functional interaction of intestinal CYP3A4 and P-glycoprotein.
Fundam Clin Pharmacol. 18:621–626. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galetin A, Burt H, Gibbons L and Houston
JB: Prediction of time-dependent CYP3A4 drug-drug interactions:
impact of enzyme degradation, parallel elimination pathways, and
intestinal inhibition. Drug Metab Dispos. 34:166–175. 2006.
View Article : Google Scholar
|
|
9
|
Wang RW, Newton DJ, Liu N, Atkins WM and
Lu AY: Human cytochrome P-450 3A4: in vitro drug-drug interaction
patterns are substrate-dependent. Drug Metab Dispos. 28:360–366.
2000.PubMed/NCBI
|
|
10
|
Walsky RL, Obach RS, Hyland R, et al:
Selective mechanism-based inactivation of CYP3A4 by CYP3cide
(PF-04981517) and its utility as an in vitro tool for delineating
the relative roles of CYP3A4 versus CYP3A5 in the metabolism of
drugs. Drug Metab Dispos. 40:1686–1697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan R, Madani S, Wei XX, Reynolds K and
Huang SM: Evaluation of cytochrome P450 probe substrates commonly
used by the pharmaceutical industry to study in vitro drug
interactions. Drug Metab Dispos. 30:1311–1319. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang W, Lin YS, McConn DJ II, et al:
Evidence of significant contribution from CYP3A5 to hepatic drug
metabolism. Drug Metab Dispos. 32:1434–1445. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dai Y, Hebert MF, Isoherranen N, et al:
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in
vitro. Drug Metab Dispos. 34:836–847. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kivistö KT, Niemi M, Schaeffeler E, et al:
CYP3A5 genotype is associated with diagnosis of hypertension in
elderly patients: data from DEBATE study. Am J Pharmacogenomics.
5:191–195. 2005. View Article : Google Scholar
|
|
15
|
Dai Y, Iwanaga K, Lin YS, et al: In vitro
metabolism of cyclosporine A by human kidney CYP3A5. Biochem
Pharmacol. 68:1889–1902. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuehl P, Zhang J, Lin Y, et al: Sequence
diversity in CYP3A promoters and characterization of the genetic
basis of polymorphic CYP3A5 expression. Nat Genet. 27:383–391.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang YP, Zuo XC, Huang ZJ, et al: CYP3A5
polymorphism, amlodipine and hypertension. J Hum Hypertens.
28:145–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shi Y, Li Y, Tang J, et al: Influence of
CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus
pharmacokinetics and early renal dysfunction in liver transplant
recipients. Gene. 512:226–231. 2013. View Article : Google Scholar
|
|
19
|
Zuo XC, Ng CM, Barrett JS, et al: Effects
of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics
in Chinese adult renal transplant recipients: a population
pharmacokinetic analysis. Pharmacogenet Genomics. 23:251–261. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Suzuki Y, Itoh H, Fujioka T, et al:
Association of plasma concentration of 4β-hydroxycholesterol with
CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in
stable kidney transplant recipients. Drug Metab Dispos. 42:105–110.
2014. View Article : Google Scholar
|
|
21
|
Bhatnagar V, Garcia EP, O’Connor DT, et
al: CYP3A4 and CYP3A5 polymorphisms and blood pressure response to
amlodipine among African-American men and women with early
hypertensive renal disease. Am J Nephrol. 31:95–103. 2010.
View Article : Google Scholar :
|
|
22
|
Kim KA, Park PW, Lee OJ, et al: Effect of
CYP3A5*3 genotype on the pharmacokinetics and
pharmacodynamics of amlodipine in healthy Korean subjects. Clin
Pharmacol Ther. 80:646–656. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Overbergh L, Valckx D, Waer M and Mathieu
C: Quantification of murine cytokine mRNAs using real time
quantitative reverse transcriptase PCR. Cytokine. 11:305–312. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Paine MF, Khalighi M, Fisher JM, et al:
Characterization of interintestinal and intraintestinal variations
in human CYP3A-dependent metabolism. J Pharmacol Exp Ther.
283:1552–1562. 1997.
|
|
25
|
Galetin A, Brown C, Hallifax D, Ito K and
Houston JB: Utility of recombinant enzyme kinetics in prediction of
human clearance: impact of variability, CYP3A5, and CYP2C19 on
CYP3A4 probe substrates. Drug Metab Dispos. 32:1411–1420. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ghosh SS, Basu AK, Ghosh S, et al: Renal
and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously
hypertensive rats. Biochem Pharmacol. 50:49–54. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Miyaki K, Wang W and Muramatsu M:
CYP3A5 polymorphism and sensitivity of blood pressure to dietary
salt in Japanese men. J Hum Hypertens. 24:345–350. 2010. View Article : Google Scholar
|
|
28
|
Ho H, Pinto A, Hall SD, et al: Association
between the CYP3A5 genotype and blood pressure. Hypertension.
45:294–298. 2005. View Article : Google Scholar
|
|
29
|
Riffel AK, Schuenemann E and Vyhlidal CA:
Regulation of the CYP3A4 and CYP3A7 promoters by members of the
nuclear factor I transcription factor family. Mol Pharmacol.
76:1104–1114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maruyama M, Matsunaga T, Harada E and
Ohmori S: Comparison of basal gene expression and induction of
CYP3As in HepG2 and human fetal liver cells. Biol Pharm Bull.
30:2091–2097. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sarkar MA and Jackson BJ: Theophylline
N-demethylations as probes for P4501A1 and P4501A2. Drug Metab
Dispos. 22:827–834. 1994.PubMed/NCBI
|
|
32
|
Badyal DK and Dadhich AP: Cytochrome P450
and drug interactions. Ind J Pharmacol. 33:248–259. 2001.
|
|
33
|
Moore LB, Parks DJ, Jones SA, et al:
Orphan nuclear receptors constitutive androstane receptor and
pregnane X receptor share xenobiotic and steroid ligands. J Biol
Chem. 275:15122–15127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Drocourt L, Ourlin JC, Pascussi JM, Maurel
P and Vilarem MJ: Expression of CYP3A4, CYP2B6, and CYP2C9 is
regulated by the vitamin D receptor pathway in primary human
hepatocytes. J Biol Chem. 277:25125–25132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mao Z, Luan X, Cao G, et al: DEC1 binding
to the proximal promoter of CYP3A4 ascribes to the downregulation
of CYP3A4 expression by IL-6 in primary human hepatocytes. Biochem
Pharmacol. 84:701–711. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tirona RG, Lee W, Leake BF, et al: The
orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated
xenobiotic induction of CYP3A4. Nat Med. 9:220–224. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsumura K, Saito T, Takahashi Y, et al:
Identification of a novel polymorphic enhancer of the human CYP3A4
gene. Mol Pharmacol. 65:326–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jover R, Bort R, Gómez-Lechón MJ and
Castell JV: Down-regulation of human CYP3A4 by the inflammatory
signal interleukin-6: molecular mechanism and transcription factors
involved. FASEB J. 16:1799–1801. 2002.PubMed/NCBI
|
|
39
|
Kacevska M, Ivanov M, Wyss A, et al: DNA
methylation dynamics in the hepatic CYP3A4 gene promoter.
Biochimie. 94:2338–2344. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Busi F and Cresteil T: CYP3A5 mRNA
degradation by nonsense mediated mRNA decay. Mol Pharmacol.
68:808–815. 2005.PubMed/NCBI
|
|
41
|
Hu YF, He J, Chen GL, et al:
CYP3A5*3 and CYP3A4*18 single nucleotide
polymorphisms in a Chinese population. Clin Chim Acta. 353:187–192.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chou FC, Tzeng SJ and Huang JD: Genetic
polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab Dispos.
29:1205–1209. 2001.PubMed/NCBI
|
|
43
|
Jounaïdi Y, Guzelian PS, Maurel P and
Vilarem MJ: Sequence of the 5′-flanking region of CYP3A5:
comparative analysis with CYP3A4 and CYP3A7. Biochem Biophys Res
Commun. 205:1741–1747. 1994. View Article : Google Scholar
|
|
44
|
Zeigler-Johnson C, Friebel T, Walker AH,
et al: CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the
etiology and severity of prostate cancer. Cancer Res. 64:8461–8467.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bajpai P, Tripathi AK and Agrawal D:
Genetic polymorphism of CYP3A5 in Indian chronic myeloid leukemia
patients. Mol Cell Biochem. 336:49–54. 2010. View Article : Google Scholar
|
|
46
|
Krusekopf S, Roots I and Kleeberg U:
Differential drug-induced mRNA expression of human CYP3A4 compared
to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol. 466:7–12. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lu C and Li AP: Species comparison in P450
induction: effects of dexamethasone, omeprazole, and rifampin on
P450 isoforms 1A and 3A in primary cultured hepatocytes from man,
Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact.
134:271–281. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pascussi JM, Drocourt L, Gerbal-Chaloin S,
et al: Dual effect of dexamethasone on CYP3A4 gene expression in
human hepatocytes. Sequential role of glucocorticoid receptor and
pregnane X receptor. Eur J Biochem. 268:6346–6358. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Roberts PJ, Rollins KD, Kashuba AD, et al:
The influence of CYP3A5 genotype on dexamethasone induction of
CYP3A activity in African Americans. Drug Metab Dispos.
36:1465–1469. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pirmohamed M, James S, Meakin S, et al:
Adverse drug reactions as cause of admission to hospital:
prospective analysis of 18,820 patients. BMJ. 329:15–19. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhao Y, Song M, Guan D, et al: Genetic
polymorphisms of CYP3A5 genes and concentration of the cyclosporine
and tacrolimus. Transplant Proc. 37:178–181. 2005. View Article : Google Scholar : PubMed/NCBI
|
